A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The hypertension and BPH intervention trial (HABIT)

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1732-1748

  Guthrie, Robert M ^a   Siegel, Richard L ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

Alphal adrenergic receptor antagonist; Antihypertensive drug; Benign prostatic hyperplasia; Combination therapy; Doxazosin

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH STATUS; HUMAN; HYPERTENSION; MALE; PROSTATE HYPERTROPHY; VERTIGO;

EID: 0032743733     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80052-6     Document Type: Article

References (38)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132: 474-479.
2. Chute CG, Panser L, Girman CJ, et al. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol. 1993;150:85-89.
3. Landsberg L. Increased sympathetic nervous system activity in the elderly. Br J Clin Pract. 1994;74(Suppl);1-3.
4. Boyle P, Napalkov N. The epidemiology of benign prostatic hyperplasia and on observations on concomitant hypertension. Scand J Urol Nephrol. 1995;29:7-12.
5. 1-adrenoceptors and uroselectivity. Prostate. 1996;30:202-215.
6. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44:413-418.
7. Esler M, Julius S, Zweifler A, et al. Mild high-renin essential hypertension: Neurogenic human hypertension? N Engl J Med. 1977;296:405-411.
8. 1-antagonists in the treatment of hypertension. Hypertension. 1989;12(Suppl):1131-1136.
9. Chapple CR, Aubry ML, James S. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol. 1989;63:487-496.
10. Lepor H. The role of alpha blockade in the therapy of benign prostatic hyperplasia. In: Lepor H, Lawson RK, eds. Prostate Diseases. Philadelphia: W.B. Saunders; 1993:170-181.
11. Eri LM, Tveter KJ. Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1995;154:923-934.
12. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554.
13. Christensen MM, Holme JB, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol. 1993;27:39-44.
14. Chapple CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol. 1994;74:50-56.
15. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol. 1995;154:105-109.
16. Holme JB, Christensen MM, Rasmussen PC, et al. 29-Week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol. 1994;28:77-82.
17. Kaplan SA, Meade-D'Alisera P, Quiñones S, et al. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology. 1995;46:512-517.
18. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
19. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA. 1993;270:713-724.
20. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs Single Drug Therapy of Hypertension Study. Revised figures and new data. Am J Hypertens. 1995;8:189-192.
21. Hosie J, Wiklund I. Managing hypertension in general practice: Can we do better? J Hum Hypertens. 1995;9(Suppl 2): S15-S18.
22. Jones JK, Gorkin L, Lian JF, et al. Discontinuation and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. Br Med J. 1995;311:293-295.
23. Searle M, Dathan R, Dean S, et al. Doxazosin in combination with atenolol in essential hypertension: A double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol. 1990;39:299-300.
24. Wing LMH, Russell AE, Tonkin AL, et al. Doxazosin and atenolol in essential hypertension: A placebo-controlled factorial study evaluating comparative and combined safety and efficacy. J Hypertens. 1991;9(Suppl 6):S495-S496.
25. Brown MJ, Dickerson JE. Synergism between alpha-1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1991;9(Suppl): S362-S363.
26. Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to anglotensin-converting enzyme inhibitor therapy. Am Heart J. 1988;116:1826-1832.
27. Brown MJ, Dickerson JE. Alpha-blockade and calcium antagonism: An effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens. 1995;13:701-707.
28. Troffa C, Manunta P, Dessi-Fulgheri P, et al. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res. 1994;55:22-31.
29. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild-to-moderate essential hypertension: A double-blind, placebo-controlled, dosc-response multicenter study. J Urol. 1995; 154:110-115.
30. Guthrie R. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia. A primary care trial. J Fam Pract. 1994;39:129-133.
31. Barry MJ, Fowler JR, O'Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Ural. 1992;148:1549-1557.
32. Mebust WK, Donovan J, Bosch R, et al. Symptom evaluation, quality of life and sexuality. In: Cockett ATK, Khoury S, Aso Y, et al, eds. The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, UK: Scientific Communication International Ltd; 1993.
33. Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand J Urol Nephrol. 1995;29:29-33.
34. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo controlled studies. Urology. 1996;48:406-415.
35. Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur Urol. 1993;24:319-326.
36. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: An update of its clinical pharmacology and therapeutic applications in the treatment of hypertension and benign prostatic hypertrophy. Drugs. 1995;49:295-320.
37. Langdon CG, Packard RS. Doxazosin in hypertension: Results of a general practice study in 4809 patients. Br J Clin Pract. 1994;48:293-298.
38. Kaplan SA. Doxazosin in the older male: Efficacy in treating benign prostatic hyper plasia. Eur Urol. 1996;29(Suppl 1):17-23.